文献速递核素与放射性配体治疗肿瘤 PET/CT

美国监管批准后[177Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的初步经验:疗效、安全性与结局预测

Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
PubMed 文献 · J Nucl Med · 2024-11-01

本研究在美国约翰斯·霍普金斯医院纳入76例临床试验外接受[177Lu]Lu-PSMA-617治疗的PSMA阳性转移性去势抵抗性前列腺癌患者,评估真实世界疗效、安全性及循环肿瘤DNA和人工智能PSMA PET/CT分析的预测价值。41%患者达PSA缓解,中位PSA无进展生存期4.1个月,中位总生存期13.7个月,3级及以上贫血12%。人工智能算法分类为非应答者的患者PSA缓解率、PSA无进展生存期和总生存期均显著低于可能应答者。

要点

  • 真实世界76例中41%达PSA缓解,中位PSA PFS 4.1个月,中位OS 13.7个月
  • 3级及以上贫血12%、血小板减少4%、中性粒细胞减少1%, transient口干28%
  • SelectPSMA分类非应答者PSA缓解率6% vs 可能应答者51%,中位OS 6.3 vs 14.5个月

核心结论

  • 监管批准后美国真实世界环境中[177Lu]Lu-PSMA-617显示出抗肿瘤活性和良好的毒性特征。
  • 基于人工智能的基线PSMA PET/CT图像分析可能改善患者选择。
  • 需要在更大队列中验证这些发现。

研究设计与样本

  • 单中心回顾性研究,在美国约翰斯·霍普金斯医院筛选临床试验外接受[177Lu]Lu-PSMA-617治疗的mCRPC患者。
  • 纳入76例PSMA阳性mCRPC患者,均有可用的结局数据。
  • 评估PSA缓解(≥50%下降)、PSA无进展生存期和总生存期,毒性按CTCAE v5.03评价。
  • 检测基线循环肿瘤DNA在同源重组修复、PI3K通路和侵袭性变异前列腺癌相关基因的突变状态与疗效的关联。
  • 使用人工智能算法SelectPSMA分析基线PSMA PET/CT图像以预测治疗结局。

主要发现

  • 74例可评估患者中30例(41%)达到PSA缓解。
  • 中位PSA无进展生存期为4.1个月(95%CI 2.0-6.2个月),中位总生存期为13.7个月(95%CI 11.3-16.1个月)。
  • 76例患者中,3级及以上贫血9例(12%)、血小板减少3例(4%)、中性粒细胞减少1例(1%), transient口干23例(28%)。
  • 存在侵袭性变异前列腺癌相关基因与更短的PSA无进展生存期相关(中位1.3 vs 6.3个月;P=0.040)。
  • 循环肿瘤DNA突变状态与其他治疗结局未见关联。

关键数值与推荐

  • PSA缓解定义为PSA较基线下降≥50%。
  • 毒性分级采用常见不良事件评价标准版本5.03。
  • SelectPSMA人工智能算法用于分析基线PSMA PET/CT图像并将患者分类为可能应答者或非应答者。

临床怎么用

  • 真实世界环境中[177Lu]Lu-PSMA-617显示出抗肿瘤活性和良好的毒性特征。
  • 基于人工智能的基线PSMA PET/CT图像分析可能改善患者选择,但原文指出需要在更大队列中验证。

局限性

  • 原文结论指出需要在更大队列中验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[177Lu]Lu-PSMA-617 was approved by the U.S. Food and Drug Administration for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Since the time of regulatory approval, however, real-world data have been lacking. This study investigated the efficacy, safety, and outcome predictors of [177Lu]Lu-PSMA-617 at a major U.S. academic center. Methods: Patients with mCRPC who received [177Lu]Lu-PSMA-617 at the Johns Hopkins Hospital outside clinical trials were screened for inclusion. Patients who underwent [177Lu]Lu-PSMA-617 and had available outcome data were included in this study. Outcome data included prostate-specific antigen (PSA) response (≥50% decline), PSA progression-free survival (PFS), and overall survival (OS). Toxicity data were evaluated according to the Common Terminology Criteria for Adverse Events version 5.03. The study tested the association of baseline circulating tumor DNA mutational status in homologous recombination repair, PI3K alteration pathway, and aggressive-variant prostate cancer-associated genes with treatment outcome. Baseline PSMA PET/CT images were analyzed using SelectPSMA, an artificial intelligence algorithm, to predict treatment outcome. Associations with the observed treatment outcome were evaluated. Results: All 76 patients with PSMA-positive mCRPC who received [177Lu]Lu-PSMA-617 met the inclusion criteria. A PSA response was achieved in 30 of 74 (41%) patients. The median PSA PFS was 4.1 mo (95% CI, 2.0-6.2 mo), and the median OS was 13.7 mo (95% CI, 11.3-16.1 mo). Anemia of grade 3 or greater, thrombocytopenia, and neutropenia were observed in 9 (12%), 3 (4%), and 1 (1%), respectively, of 76 patients. Transient xerostomia was observed in 23 (28%) patients. The presence of aggressive-variant prostate cancer-associated genes was associated with a shorter PSA PFS (median, 1.3 vs. 6.3 mo; P = 0.040). No other associations were observed between circulating tumor DNA mutational status and treatment outcomes. Eighteen of 71 (25%) patients classified by SelectPSMA as nonresponders had significantly lower rates of PSA response than patients classified as likely responders (6% vs. 51%; P < 0.001), a shorter PSA PFS (median, 1.3 vs. 6.3 mo; P < 0.001), and a shorter OS (median, 6.3 vs. 14.5 mo; P = 0.046). Conclusion: [177Lu]Lu-PSMA-617 offered in a real-world setting after regulatory approval in the United States demonstrated antitumor activity and a favorable toxicity profile. Artificial-intelligence-based analysis of baseline PSMA PET/CT images may improve patient selection. Validation of these findings on larger cohorts is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gafita A, Voter A, Shesadri S, et al. Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction. J Nucl Med. 2024. PMID: 39299783. doi:10.2967/jnumed.124.267723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。